Shattuck Labs/STTK

$9.65

9.96%
-
1D1W1MYTD1YMAX

About Shattuck Labs

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. SL-172154 is in an ongoing Phase I clinical trial for the treatment of patients with ovarian cancer. It is also evaluating SL-172154 in an ongoing Phase I clinical trial for the treatment of patients with certain hematologic malignancies, including acute myeloid leukemia (AML), and higher-risk myelodysplastic syndromes (HR-MDS). The Company is also advancing a Gamma Delta T Cell Engager, GADLEN platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer.

Ticker

STTK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Taylor Schreiber

Employees

105

Headquarters

Austin, United States

Shattuck Labs Metrics

BasicAdvanced
$458.13M
Market cap
-
P/E ratio
-$2.24
EPS
2.13
Beta
-
Dividend rate

What the Analysts think about Shattuck Labs

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 4 analysts.
60.62% upside
High $28.00
Low $10.00
$9.65
Current price
$15.50
Average price target

Shattuck Labs Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-4,583.33% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$600K
200%
Net income
$-27.5M
29.11%
Profit margin
-4,583.33%
-56.96%

Shattuck Labs Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 27.84%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.49
-$0.50
-$0.65
-$0.41
-
Expected
-$0.63
-$0.52
-$0.52
-$0.57
-$0.51
Surprise
-22.15%
-3.33%
25.2%
-27.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Shattuck Labs stock

Buy or sell Shattuck Labs stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing